Notice of GM

RNS Number : 2725C

ValiRx PLC

27 June 2016

 

ValiRx Plc

("ValiRx" or the "Company")

Shareholder Circular and Notice of General Meeting

London, UK. 27^th June 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that it has today published and posted to shareholders a circular in relation to a forthcoming General Meeting, due to be held at the offices of DAC Beachcroft LLP at 100 Fetter Lane, London EC4A 1BN at 11:30 a.m. on 12th July 2016.

The directors will propose at the General Meeting a shareholder resolution seeking consent for the dis-application of pre-emptive rights.

A copy of the Circular is available on the Company's website.

*** ENDS ***

For more information, please contact:

ValiRx plc	Tel: [phone] www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: [phone]
Tarquin Edwards, Head of Communications.	Tel: [phone] [e-mail]
Mark Treharne, Corporate Development Manager	Tel: [phone] [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser)	Tel: [phone]
Liam Murray / Richard Nash
Northland Capital Partners Limited (Broker)	Tel: [phone]
Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking)

 

END

 

 

NOGAKQDKOBKDQAB